Kornimate/medical-research-clean huggingface dataset:
evaluation of pain and anxiety in patients with an invasive procedure in emergencies

Conditions: Virtual Reality

Summary: a large number of patients presenting to the emergency department will have an invasive or potentially painful treatment (suture, urinary catheterization, reduction of dislocation or fracture). this care is a source of pain and anxiety for patients. since 1998, the management of pain is a public health priority in france. law no. 2002-3003 of 4 march 2002 on the rights of the sick and the quality of the health system has made pain management a right: "everyone has the right to receive care to relieve his pain. this must be in all circumstances prevented, evaluated, taken into account and treated ". in emergency departments, the use of antalgic drug treatments and local anesthetics is systematic.

other techniques to create diversions proposed in the recommendations of the french society of emergency medicine for the management of wounds in emergencies can be used to improve the experience of patients: the use speech during the gesture or certain forms of hypnosis. pain and anxiety are two important factors to integrate to improve the management of patients in emergencies. to improve pain and anxiety, distraction is a technique that can be used. virtual reality is a distraction technique not yet frequently used but studied. it combines the visual and the auditory allowing immersion in a virtual world thanks to a helmet retranscribing a three-dimensional image. the diversion of attention through the use of virtual reality allows the patient to immerse themselves in a fictional environment through a mask on the eyes inhibiting the vision of the outside world and a headphone reducing external sounds and reinforcing the mechanism of 'immersion. the use of the virtual reality headset has already shown benefits during pain care in burn patients and children. the virtual reality headset has not yet been studied as a distraction tool for invasive and potentially painful care in emergencies.

Eligibility criteria:
inclusion criteria: * man and woman (age ≥ 18 years) * francophone * patient with medical insurance * patient with a wound requiring trunk or limb sutures * or male patient requiring an urinary catheter * patient with cutaneous and subcutaneous wounds (deep plane possible) but without repair of noble tissues (tendons or fasciae) with no limit on the number of points to be made (i.e. without impact on the main endpoint). exclusion criteria: * patient with a wound or skin infection of the face * patients with nausea, vomiting, dizziness * patients with a history of neurological disorders with epilepsy * patient whose investigator judges that he can not wear a virtual reality helmet * patient under tutorship or curatorship * patient deprived of liberty * refusal to participate in the study.

Keywords: pain anxiety
sequential treatment with cd20/cd22/cd10-cart after cd19-cart treatment base on mrd in relapsed/refractory b-all

Conditions: Therapy Related Leukemia

Summary: cd19-negative b-all relapses after cd19 car t-cell treatment have occurred in some patients. cd20/cd22/cd10 is still expressed in cd19 negative b-all cells which means these cd molecules may become new targets in treatment of cd19-negative relapse of b-all. thus sequential treatment with cd20/cd22/cd10-cart after cd19-cart treatment in relapsed/refractory b-all will kill and eliminate cd19 negative b-all cells and prolong the remission time.

b-cell acute lymphoblastic leukemia is the most common type of leukemia and the prognosis of relapsed/refractory b-all is poor. chimeric antigen receptor-transduced t cell (car-t) therapy is one of revolutionary targeted immunotherapy. cd19 car-t is the most commonly used engineered t cell in b-all. the treatment effect is significant and far more than traditional therapy in relapsed/refractory b-all. however, the remission time after cd19 car-t infusion is short.cd19-positive and cd19-negative b-all relapses after cd19 car t-cell treatment have occurred in some patients the cause of relapse after car-t infusion is minimal residual disease (mrd) which will induce cd19 negative relapse. cd20/cd22/cd10 is still expressed in cd19 negative b-all cells which means these cd molecules may become new targets in treatment of cd19 negative relapse of b-all. thus sequential treatment with cd20/cd22/cd10-cart after cd19-cart treatment in relapsed/refractory b-all will kill and eliminate cd19 negative b-all cells and prolong the remission time.

Eligibility criteria:
inclusion criteria: 1. relapsed/refractory b-all patients 2. did not achieve complete remission after 2 times of standard plan chemotherapy 3. relapsed after first induction chemotherapy 4. did not response to chemotherapy before hsct or relapsed after hsct 5. cannot receive allo-hsct or refuse to receive allo-hsct 6. cell phenotype is cd19 and cd20/cd22/cd10/cd70 positive (single or combined) 7. estimated survival time is more than 3 months in leukemia 8. volunteered for this clinical trail and signed a consent form exclusion criteria: 1. mrd was negative while the cell phenotype was cd19 expressed 2. patients with severe insufficient cardiac, pulmonary and hepatorenal functions 3. patients with severe mental illness, neurological disease or infectious disease 4. patients with gvhd was taking immunosuppressants 5. pregnant or lactating women 6. patients have received other genetic therapy products 7. transfection efficiency was less than 30% 8. any situation may do harm to the subjects or interfere the results

Keywords: cd19-cart cd20-cart cd10-cart cd22-cart relapsed/refractory b-all mrd cd70-cart
sleep disturbance and sleep quality in women with fibromyalgia syndrome

Conditions: Fibromyalgia Syndrome

Summary: the purpose of this week long study is to describe sleep and problems with sleep in women diagnosed with fibromyalgia syndrome.

at least 50 women over 18 years of age are invited to volunteer in this study. sleep quality and problems with sleep will be described using several kinds of measures. questionnaires on sleep and fibromyalgia will be completed by the volunteer. in addition, the volunteer will complete a sleep diary for at least 7 days and wear an actiwatch (a wrist watch like device that measures sleep). at completion of the study, participants will be provided a print out of their sleep obtained from the actiwatch. participants may not be in the study if they work night shift (11 pm - 7 am) or have been diagnosed with a condition called sleep apnea. participants need not live in kentucky to participate in this study.

Eligibility criteria:
inclusion criteria: * women 18 years old; diagnosed with fibromyalgia; exclusion criteria: * volunteer works night shift (11pm - 7am); * volunteer has been diagnosed with sleep apnea.

Keywords: fibromyalgia syndrome
bright light: a novel treatment for anxiety

Conditions: Anxiety; Depression; Sleep

Summary: the primary aim of this research was to examine the influence of bright light on anxiety in high-anxious young adults. in an acute exposure study, participants were randomly assigned to 45 min of either (1) bright light (3,000 lux) or (2) a placebo inactivated negative ion generator. treatments were initiated ≤1 hr after awakening. at 10 min before and 30 min after the treatments, state anxiety, mood, and blood pressure were assessed. following the acute exposure study, participants performed a 5-week study. following a a 1-week baseline, participants were randomly assigned to four weeks of daily exposure to either (1) bright light (45 min/day; 3,000 lux) or (2) placebo inactivated negative ion generator, which were initiated ≤1 hr after awakening. before and after the experiment, clinical ratings were conducted with the hamilton anxiety scale, the hamilton depression scale, and the clinical global impressions scale (cgi). following baseline, and following each week of treatment, blood pressure, as well as questionnaires for state anxiety, depression, mood, sleep, and side effects were assessed.


Eligibility criteria:
inclusion criteria: * having a level of trait anxiety \[spielberger state-trait anxiety inventory (form y1)\]{23642} that was ≥ the 75th percentile for their age (i.e., ≥ 46 and ≥ 44 for women and men, respectively) exclusion criteria: * current treatment for anxiety or depression; * history of bipolar disorder, mania, or psychotic disorders; * history of winter depression, which might bias towards positive response to light; * hypertension; * ophthalmic abnormalities; and * usual exposure to high levels of light such that the intervention would add little to usual exposure.

Keywords: anxiety phototherapy psychic anxiety
the grade capillary blood collection pilot study

Conditions: Type 2 Diabetes

Summary: this pilot study is planned to validate the comparability of hba1c results obtained from whole blood collection via venous phlebotomy versus a capillary collection of whole blood. the participant will self-collect capillary blood into hba1c prep vials containing a buffer; these prep vials will be sent to the cbl at ambient temperature via us postal system (usps) mail. the feasibility of self-collection of these capillary samples by grade participants will also be evaluated.


Eligibility criteria:
inclusion criteria: * current grade participant with a scheduled follow-up visit exclusion criteria: * grade participants attending first quarterly (month 3) visit or an annual visit
prime-boost dose scheduling trial for human gm-csf gene transduced irradiated prostate allogeneic cancer vaccine (allogeneic prostate gvax®) in patients with hormone-refractory prostate cancer

Conditions: Prostate Cancer

Summary: the objective of this study is to evaluate the safety and efficacy of a prime-boost dose schedule of human gm-csf gene transduced irradiated prostate allogeneic cancer vaccine (allogeneic prostate gvax®) as measured by standard toxicity evaluation, changes in psa, and tumor responses. additional objectives are to measure the time to psa and/or clinical disease progression as well as local and systemic immune responses to the vaccine.


Eligibility criteria:
inclusion criteria: * diagnosis of adenocarcinoma prostate cancer * prostate cancer deemed to be unresponsive or refractory to hormone therapy * an ecog performance status of 0 or 1 exclusion criteria: * transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer * previous chemotherapy, biological or immunotherapy for cancer * previous gene therapy for cancer * significant cancer related pain

Keywords: prostate cancer advanced prostate cancer metastatic hormone-refractory gvax vaccine allogeneic cells
glucose homeostasis pre and post bariatric surgery

Conditions: Morbid Obesity

Summary: the investigators wish to study the effects of three forms of bariatric surgery: roux-en-y gastric bypass, sleeve gastrectomy, and gastric banding. the surgery is not part of the clinical trial. if your insurance does not cover the procedure, then you are responsible for payment of the surgical process. we are doing pre and post surgery testing to provide a better understanding of the effect of bariatric surgery-induced weight loss on metabolic function.

bariatric surgery is the most effective weight loss therapy for obesity. moreover, the early improvement in insulin sensitivity and the resolution of type 2 diabetes after bariatric surgery has led to the hypothesis that bariatric surgery has specific beneficial effects on glucose homeostasis beyond weight loss alone. however, this hypothesis has never been adequately evaluated in human subjects. therefore, the primary goal of this proposal is to provide a better understanding of the effect of bariatric surgery-induced weight loss on insulin action and pancreatic beta cell function.

Eligibility criteria:
inclusion criteria: * bmi ≥ 35 kg/m² * on stable dose of medications for at least 4 weeks before the pre-surgery metabolic studies exclusion criteria: * smokes \> 7 cigarettes per day * previous malabsorptive or restrictive intestinal surgery * pregnant or breastfeeding * recent history of neoplasia (\< 5 years ago) * have malabsorptive syndromes and inflammatory intestinal disease * diabetes mellitus * show signs of oral disease or xerostomia (i.e., dry mouth) * history of chronic rhinitis * on medication that might affect metabolism * severe organ dysfunction

Keywords: obesity gastric bypass gastric banding weight loss insulin sensitivity sleeve gastrectomy fibroblast growth factor 21 fibroblast growth factor 19
sufentanil for anesthesia induction in continuous remifentanil anesthesia

Conditions: Postoperative Pain

Summary: the appropriate management of postoperative pain is recognized as an important clinical challenge with implications beyond humanitarian issues. evidence shows that effective postoperative analgesia is associated with physiological benefits to the patient, shortened length of hospital stay and lower rates of in-hospital complications, such as pneumonia, delirium and persistent pain after surgery. however, despite the availability of several analgesic drugs and strategies the prevention and treatment of postoperative pain is often suboptimal. remifentanil is a potent short acting opioid commonly used in continuous infusion for anesthesia for several surgical procedures. remifentanil has been extensively advocated as a means to provide quick patient awakening in the immediate postoperative period with a very low risk of respiratory depression. yet it does not provide residual analgesia and postoperative pain is a major concern. in order to overcome this limitation, practicing anesthesiologists frequently give patients a single dose of sufentanil, a long acting opioid, during the induction of anesthesia where remifentanil will be used in continuous infusion. however the effectiveness of this strategy still lacks evidence from controlled clinical trials.

we propose the current randomized clinical trial to assess the analgesic effectiveness of sufentanil administered as a single dose during the induction of anesthesia for the management of postoperative pain in patients undergoing open abdominal surgery performed with continuous infusion of remifentanil.

Eligibility criteria:
inclusion criteria: * physical status (american society of anesthesiologists) 1, 2 or 3 * age 18 years and older * patients selected for open abdominal surgery under general total intravenous anesthesia exclusion criteria: * physical status (american society of anesthesiologists) 4 * patients undergoing other anesthesia technic (subarachnoid, epidural, nerve block, etc) * history of anaphylactic reaction after use of tramadol, dipyrone, propofol, rocuronium, dexamethasone, sufentanil, remifentanil or morphine * chronic uso of drugs that are associated with major increases in the activity of p450 isozymes (carbamazepine, phenobarbital, rifampin, tobacco, phenytoin, hypericum perforatum) * previous history of drug addiction * alcoholism

Keywords: postoperative pain patient controlled analgesia hyperalgesia remifentanil sufentanil morphine abdominal surgery safety
evaluation of 3d surface scanning for virtual-ct based radiation therapy treatment planning

Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Summary: this study evaluates if three dimensional (3d) surface images can be used instead of the standard computed tomography (ct) scans for treatment planning in electron radiation therapy. 3d scanning has previously been used by several groups to design patient-specific devices to be 3d printed, and as has shown excellent agreement with ct obtained surfaces. using 3d surface imaging instead of x-ray based ct, benefits include: no ionizing radiation used to produce images, shorter time between patient consultation and treatment, and ability to produce and evaluate patient-specific devices for electron therapy earlier in the treatment planning process. this study may help researchers learn how 3d surface scanning may be used to produce a virtual ct image of patient surfaces, and accurately replace traditional planning ct for treatment planning of electron based radiation therapy.

primary objectives: i. develop and benchmark the necessary software to convert a 3d scan to a virtual ct. ii. compare the spatial accuracy of virtual cts from 3d scans to the planning ct. iii. compare radiation treatment plans based on the virtual cts from aim 2 to treatment plans based on the actual planning cts. outline: this is an observational study. patients undergo 3d surface scans on study. patient's medical records are also reviewed on study.

Eligibility criteria:
inclusion criteria: * adults (18 years old or older) * capable of consent * receiving electron therapy and a planning ct scan * consent to two 3d surface scans of treatment area exclusion criteria: * pediatric patients * mentally incapable of study consent * receiving electron radiation for a breast cancer boost * receiving electrons for total skin electron therapy * patients with epilepsy or other seizure disorders
the safety and effectiveness of breath-o lenses

Conditions: Myopia; Safety Issues

Summary: in hong kong, approximately 80% of children are myopic by the end of childhood. there is intense interest currently in the potential role of peripheral defocus as a clinical treatment to slow myopia progression. one of the most successful treatments for myopia is orthokeratology. currently, breath-o correct lenses are new designed ready-made orthokeratology lenses. this study is to evaluate the safety of wearing this new orthokeratology lens and the effectiveness of clinical performance in young adult.

short-sightedness (myopia) is the most common refractive error in the world. in hong kong, approximately 80% of children are myopic by the end of childhood. current treatment strategies to control (i.e. slow) myopia progression in children are primarily designed to harness the natural "emmetropization" process, in which visual feedback from retinal image clarity regulates the rate of eye growth. there is intense interest currently in the potential role of peripheral defocus as a clinical treatment to slow myopia progression, not least since this approach permits clear central vision. one of the most successful treatments for myopia is orthokeratology, which is a therapy of using custom-made rigid gas permeable contact lens. the special design of this contact lens can reshape the corneal profile to minimize the central refractive error while producing beneficial peripheral defocus. currently, breath-o correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material. this study is to evaluate the safety of wearing this new orthokeratology lens and the effectiveness of clinical performance in young adult.

Eligibility criteria:
inclusion criteria: 1. refractive error: spherical: normally -1.00d to -4.00d (maximum up to -5.00d); cylindrical: normally half of sph (against-the-rule astigmatism.: lower than -0.75d) (maximum up to -1.50d) 2. best corrected visual acuity: monocular etdrs 0.0 or better 3. ocular health: no ocular abnormality, no contra-indications for overnight orthokeratology lens wear, no refractive surgery 4. general health: no systemic diseases 5. requirement: no history of orthokeratology lens wearing. agree to participate in this study and willing to wear the orthokeratology lenses overnight in accordance with the instructions given and to come back for follow up within the study period

Keywords: myopia orthokeratology
combined haploidentical-cord blood transplantation for adults and children

Conditions: Leukemia; Myelodysplastic Syndrome; Multiple Myeloma; Lymphoma

Summary: the primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. the secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease (gvhd).


Eligibility criteria:
inclusion criteria: patients will be eligible for this study if they have any one of the diseases that are known to be cured after allogeneic stem cell transplantation. 1. relapsed or refractory acute leukemia (myeloid or lymphoid) 2. acute leukemia in first remission at high-risk for recurrence 3. chronic myelogenous leukemia in accelerated phase or blast-crisis 4. chronic myelogenous leukemia in chronic phase 5. recurrent or refractory malignant lymphoma or hodgkin lymphoma 6. chronic lymphocytic leukemia, relapsed or with poor prognostic features 7. multiple myeloma 8. myelodysplastic syndrome 9. chronic myeloproliferative disease 10. hemoglobinopathies 11. aplastic anemia exclusion criteria: 1. zubrod performance status \> 2 2. life expectancy is severely limited by concomitant illness 3. patients with severely decreased lvef or impaired pulmonary function tests(pft's) 4. estimated creatinine clearance \<50 ml/min 5. serum bilirubin\> 2.0 mg/dl or sgpt \>3 x upper limit of normal 6. evidence of chronic active hepatitis or cirrhosis 7. hiv-positive 8. patient is pregnant 9. patient or guardian not able to sign informed consent

Keywords: appropriate candidate for transplantation an hla-identical related or unrelated donor cannot be identified within an appropriate time frame.
intravenous ibuprofen versus ketorolac in bariatric surgery

Conditions: Postoperative Pain; Bariatric Surgery Candidate

Summary: the aim of the current study is to compare the analgesic effects of both drugs in patients with obesity undergoing bariatric surgery.

upon arrival to the operating room, routine monitors (electrocardiogram, pulse oximetry, and non-invasive blood pressure monitor) will be applied; intravenous line will be secured, and prophylactic antiemetic will be provided in the form of slow intravenous injection of 5 mg dexamethasone drugs. anesthesia anesthesia will be induced with 2 mg/kg propofol, 2 mcg/kg fentanyl (lean body weight), and tracheal intubation will be facilitated by 0.6 mg/kg ideal body weight rocuronium after loss of consciousness. anesthesia will be maintained with isoflurane 1-1.2% in oxygen and 0.1 mg/kg rocuronium every 30 minutes. fentanyl boluses of 1 mcg/kg will be given if heart rate or/and systolic blood pressure \>120% of baseline. postoperatively, pain assessments using the visual analogue scale (vas) will be performed at rest and during movement (knee flexion) at 0.5, 4, 10, 18, and 24 h after leaving the operating room. if the vas score is \> 3 intravenous nalbuphine 0.1-0.2 mg/kg (lean body weight) titrated to response with maximum single dose of 20 mg and maximum daily dose of 160 mg. intravenous ondansetron 4 mg will be given to treat postoperative nausea or vomiting

Eligibility criteria:
inclusion criteria: * adult (18-65 years) patients * body mass index ≥35 kg/m2 * scheduled for laparoscopic bariatric surgery exclusion criteria: * american society of anesthesiologists (asa) physical class iv, * severe cardiac comorbidity (impaired contractility with ejection fraction \< 50%, heart block, significant arrhythmias, tight valvular lesions), * known obstructive sleep apnea or patients with stop-bang score ≥5, * baseline spo2 \<95%, * renal impairment, * allergy to any of study's drugs, * history of gastrointestinal bleeding or ulceration, or inflammatory bowel disease